FindTrial
Sign In

experimental group:experimental group

2 trials

Sponsors

The Affiliated Panyu Central Hospital, Guangzhou Medical University, Renmin Hospital of Wuhan University

Conditions

Advanced non-squamous non-small cell lung cancer (NSCLC) with negative driver genes that has developed secondary resistance after first-line treatment with a combination of PD-1/L1 inhibitors and a platinum-based doublet regimen.ST-Elevated Myocardial Infarction

Phase 2

A multicenter, single-arm, phase II exploratory study (TELESCOPE) of tislelizumab combined with bevacizumab and nab-paclitaxel as second-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) patients with negative driver genes who develop secondary resistance after first-line treatment with a PD-1/L1 inhibitor combined with a platinum-based doublet regimen
Active, not recruitingChiCTR2500099531
The Affiliated Panyu Central Hospital, Guangzhou Medical UniversityAdvanced non-squamous non-small cell lung cancer (NSCLC) with negative driver genes that has developed secondary resistance after first-line treatment with a combination of PD-1/L1 inhibitors and a platinum-based doublet regimen.
Start: 2025-05-01Updated: 2025-03-31

Unknown Phase

Withdraw due to duplicate registration (NCT07361783). Effectiveness and Safety of Early Administration of Heparin at First Medical Contact for ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: a Multicenter, Prospective, Randomized, Controlled Study(HELP-PCI 2)
RecruitingChiCTR2500114432
Renmin Hospital of Wuhan UniversityST-Elevated Myocardial Infarction
Start: 2025-08-13Updated: 2026-06-29